Eli Lilly And Co (NYSE:LLY) Releases Quarterly Earnings Results, Beats Expectations By $0.31 EPS

Eli Lilly And Co (NYSE:LLY) released its quarterly earnings data on Thursday. The company reported $1.89 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.31, MarketWatch Earnings reports. The company had revenue of $5.50 billion for the quarter, compared to analyst estimates of $5.77 billion. Eli Lilly And Co had a return on equity of 200.78% and a net margin of 24.48%. The company’s revenue was down 2.4% compared to the same quarter last year. During the same period in the prior year, the company posted $1.50 EPS. Eli Lilly And Co updated its FY 2020
Pre-Market guidance to 7.20-7.40 EPS and its FY20 guidance to $7.20-$7.40 EPS.

Shares of LLY stock traded down $2.71 during trading hours on Friday, reaching $150.29. The company had a trading volume of 5,342,109 shares, compared to its average volume of 2,630,266. The company has a 50 day moving average of $160.88 and a 200 day moving average of $148.62. The company has a debt-to-equity ratio of 4.37, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a market cap of $143.74 billion, a price-to-earnings ratio of 24.40, a P/E/G ratio of 1.34 and a beta of 0.26. Eli Lilly And Co has a 1-year low of $101.36 and a 1-year high of $170.75.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $0.74 dividend. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.97%. The ex-dividend date is Thursday, August 13th. Eli Lilly And Co’s dividend payout ratio (DPR) is currently 49.01%.

LLY has been the topic of a number of research analyst reports. Guggenheim upgraded Eli Lilly And Co from a “neutral” rating to a “buy” rating and set a $182.00 price target on the stock in a research report on Tuesday, June 16th. JPMorgan Chase & Co. increased their price target on Eli Lilly And Co from $175.00 to $190.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 17th. Bank of America restated a “buy” rating and set a $180.00 price target on shares of Eli Lilly And Co in a research report on Friday, June 19th. Morgan Stanley lowered Eli Lilly And Co from an “overweight” rating to an “equal weight” rating in a research report on Sunday, April 19th. Finally, UBS Group lowered Eli Lilly And Co from a “buy” rating to a “neutral” rating and increased their price target for the stock from $157.00 to $158.00 in a research report on Monday, April 20th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Eli Lilly And Co has an average rating of “Buy” and an average target price of $168.58.

In related news, SVP Alfonso G. Zulueta sold 17,000 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $162.94, for a total transaction of $2,769,980.00. Following the sale, the senior vice president now owns 39,646 shares of the company’s stock, valued at approximately $6,459,919.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 12,961 shares of the firm’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $169.69, for a total value of $2,199,352.09. Following the sale, the insider now directly owns 111,132,563 shares in the company, valued at approximately $18,858,084,615.47. The disclosure for this sale can be found here. In the last three months, insiders sold 555,236 shares of company stock worth $91,393,391. 0.09% of the stock is currently owned by company insiders.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: Marijuana Stocks Investing Considerations

Earnings History for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.